Oncology Institute Inc/the (TOI)

$0.52

-0.02

(-3.88%)

Market is closed - opens 7 PM, 19 Jul 2024

Performance

  • $0.50
    $0.57
    $0.52
    downward going graph

    3.54%

    Downside

    Day's Volatility :12.54%

    Upside

    9.33%

    downward going graph
  • $0.41
    $2.66
    $0.52
    downward going graph

    21.73%

    Downside

    52 Weeks Volatility :84.7%

    Upside

    80.45%

    downward going graph

Returns

PeriodOncology Institute Inc/theSector (Health Care)Index (Russel 2000)
3 Months
-56.02%
8.7%
0.0%
6 Months
-74.72%
8.0%
0.0%
1 Year
-30.11%
14.0%
0.0%
3 Years
-94.56%
17.0%
-18.2%

Highlights

Market Capitalization
36.7M
Book Value
$0.56
Earnings Per Share (EPS)
-0.81
Wall Street Target Price
2.0
Profit Margin
-21.29%
Operating Margin TTM
-18.99%
Return On Assets TTM
-17.68%
Return On Equity TTM
-104.45%
Revenue TTM
342.7M
Revenue Per Share TTM
4.64
Quarterly Revenue Growth YOY
24.2%
Gross Profit TTM
52.1M
EBITDA
-56.0M
Diluted Eps TTM
-0.81
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.42
EPS Estimate Next Year
-0.16
EPS Estimate Current Quarter
-0.12
EPS Estimate Next Quarter
-0.09

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 5 Wall street analysts offering stock ratings for Oncology Institute Inc/the(by analysts ranked 0 to 5 stars)
Based on 5 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
4
4
4
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 284.62%

Current $0.52
Target $2.00

Company Financials

FY18Y/Y Change
Revenue
113.2M
-
Net Income
3.9M
-
Net Profit Margin
3.49%
-
FY19Y/Y Change
Revenue
155.4M
↑ 37.33%
Net Income
-4.0M
↓ 201.86%
Net Profit Margin
-2.59%
↓ 6.08%
FY20Y/Y Change
Revenue
187.5M
↑ 20.66%
Net Income
-14.3M
↑ 256.13%
Net Profit Margin
-7.64%
↓ 5.05%
FY21Y/Y Change
Revenue
203.0M
↑ 8.26%
Net Income
-10.9M
↓ 23.7%
Net Profit Margin
-5.38%
↑ 2.26%
FY22Y/Y Change
Revenue
252.5M
↑ 24.37%
Net Income
1.7M
↓ 115.16%
Net Profit Margin
0.66%
↑ 6.04%
FY23Y/Y Change
Revenue
324.2M
↑ 28.42%
Net Income
-67.9M
↓ 4196.38%
Net Profit Margin
-20.93%
↓ 21.59%
Q4 FY22Q/Q Change
Revenue
71.4M
↑ 9.92%
Net Income
-9.5M
↑ 255.35%
Net Profit Margin
-13.3%
↓ 9.18%
Q1 FY23Q/Q Change
Revenue
76.2M
↑ 6.68%
Net Income
-30.0M
↑ 215.7%
Net Profit Margin
-39.37%
↓ 26.07%
Q2 FY23Q/Q Change
Revenue
80.2M
↑ 5.29%
Net Income
-16.9M
↓ 43.67%
Net Profit Margin
-21.06%
↑ 18.31%
Q3 FY23Q/Q Change
Revenue
82.0M
↑ 2.26%
Net Income
-17.4M
↑ 3.09%
Net Profit Margin
-21.23%
↓ 0.17%
Q4 FY23Q/Q Change
Revenue
85.8M
↑ 4.57%
Net Income
-15.3M
↓ 12.08%
Net Profit Margin
-17.85%
↑ 3.38%
Q1 FY24Q/Q Change
Revenue
94.7M
↑ 10.35%
Net Income
-16.3M
↑ 6.26%
Net Profit Margin
-17.19%
↑ 0.66%
FY19Y/Y Change
Total Assets
59.5M
-
Total Liabilities
17.3M
-
FY20Y/Y Change
Total Assets
65.7M
↑ 10.36%
Total Liabilities
37.6M
↑ 117.29%
FY21Y/Y Change
Total Assets
203.4M
↑ 209.7%
Total Liabilities
99.3M
↑ 164.13%
FY22Y/Y Change
Total Assets
263.7M
↑ 29.65%
Total Liabilities
139.1M
↑ 40.08%
FY23Y/Y Change
Total Assets
219.4M
↓ 16.81%
Total Liabilities
162.4M
↑ 16.77%
Q4 FY22Q/Q Change
Total Assets
263.7M
↓ 7.07%
Total Liabilities
139.1M
↓ 10.78%
Q1 FY23Q/Q Change
Total Assets
234.6M
↓ 11.04%
Total Liabilities
136.2M
↓ 2.04%
Q2 FY23Q/Q Change
Total Assets
230.0M
↓ 1.99%
Total Liabilities
145.2M
↑ 6.61%
Q3 FY23Q/Q Change
Total Assets
218.4M
↓ 5.05%
Total Liabilities
146.5M
↑ 0.87%
Q4 FY23Q/Q Change
Total Assets
219.4M
↑ 0.49%
Total Liabilities
162.4M
↑ 10.85%
Q1 FY24Q/Q Change
Total Assets
204.5M
↓ 6.78%
Total Liabilities
163.2M
↑ 0.52%
FY18Y/Y Change
Operating Cash Flow
5.6M
-
Investing Cash Flow
2.5M
-
Financing Cash Flow
-8.2M
-
FY19Y/Y Change
Operating Cash Flow
3.6M
↓ 35.92%
Investing Cash Flow
-1.2M
↓ 148.4%
Financing Cash Flow
-1.8K
↓ 99.98%
FY20Y/Y Change
Operating Cash Flow
508.2K
↓ 85.94%
Investing Cash Flow
-8.8M
↑ 634.22%
Financing Cash Flow
11.9M
↓ 655447.3%
FY21Y/Y Change
Operating Cash Flow
-32.7M
↓ 6530.05%
Investing Cash Flow
-230.0M
↑ 2500.6%
Financing Cash Flow
154.0M
↑ 1195.51%
FY22Y/Y Change
Operating Cash Flow
-61.8M
↑ 88.97%
Investing Cash Flow
-131.6M
↓ 42.78%
Financing Cash Flow
92.2M
↓ 40.13%
Q4 FY22Q/Q Change
Operating Cash Flow
-14.0M
↓ 31.38%
Investing Cash Flow
-32.6M
↓ 62.89%
Financing Cash Flow
-847.0K
↓ 100.8%
Q1 FY23Q/Q Change
Operating Cash Flow
-15.5M
↑ 10.4%
Investing Cash Flow
24.9M
↓ 176.46%
Financing Cash Flow
-1.7M
↑ 101.77%
Q2 FY23Q/Q Change
Operating Cash Flow
-8.7M
↓ 43.96%
Investing Cash Flow
24.9M
↑ 0.0%
Financing Cash Flow
-2.6M
↑ 52.19%

Technicals Summary

Sell

Neutral

Buy

Oncology Institute Inc/the is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Oncology Institute Inc/the
Oncology Institute Inc/the
32.89%
-74.72%
-30.11%
-94.56%
-94.42%
Fresenius Medical Care Ag
Fresenius Medical Care Ag
0.81%
2.22%
-27.54%
-50.93%
-48.38%
Hca Holdings, Inc.
Hca Holdings, Inc.
-5.18%
13.4%
11.47%
48.41%
128.69%
Tenet Healthcare Corp. 
Tenet Healthcare Corp. 
-2.97%
66.0%
65.85%
106.36%
618.14%
Universal Health Services Inc.
Universal Health Services Inc.
-3.56%
17.51%
20.1%
25.62%
37.99%
Davita Healthcare Partners Inc.
Davita Healthcare Partners Inc.
-1.78%
32.51%
31.57%
18.55%
146.18%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Oncology Institute Inc/the
Oncology Institute Inc/the
47.33
NA
NA
-0.42
-1.04
-0.18
NA
0.56
Fresenius Medical Care Ag
Fresenius Medical Care Ag
21.9
21.9
0.39
1.51
0.05
0.03
0.03
47.4
Hca Holdings, Inc.
Hca Holdings, Inc.
15.9
15.9
1.44
20.98
0.85
0.11
0.01
-6.14
Tenet Healthcare Corp. 
Tenet Healthcare Corp. 
5.18
5.18
1.74
8.98
0.54
0.07
NA
35.35
Universal Health Services Inc.
Universal Health Services Inc.
15.62
15.62
1.87
13.79
0.13
0.06
0.0
93.48
Davita Healthcare Partners Inc.
Davita Healthcare Partners Inc.
15.63
15.63
1.16
9.32
0.43
0.06
NA
10.56
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Oncology Institute Inc/the
Oncology Institute Inc/the
Buy
$36.7M
-94.42%
47.33
-21.29%
Fresenius Medical Care Ag
Fresenius Medical Care Ag
Hold
$11.6B
-48.38%
21.9
2.48%
Hca Holdings, Inc.
Hca Holdings, Inc.
Buy
$83.5B
128.69%
15.9
8.2%
Tenet Healthcare Corp. 
Tenet Healthcare Corp. 
Buy
$13.0B
618.14%
5.18
12.54%
Universal Health Services Inc.
Universal Health Services Inc.
Hold
$12.3B
37.99%
15.62
5.57%
Davita Healthcare Partners Inc.
Davita Healthcare Partners Inc.
Hold
$12.1B
146.18%
15.63
6.61%

Insights on Oncology Institute Inc/the

  • Increasing Revenue

    Revenue is up for the last 13 quarters, 48.58M → 94.66M (in $), with an average increase of 5.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -15.31M → -16.27M (in $), with an average decrease of 6.3% per quarter

  • Vs THC

    In the last 1 year, Tenet Healthcare Corp.  has given 65.9% return, outperforming this stock by 96.0%

  • Vs THC

    In the last 3 years, Tenet Healthcare Corp.  has given 100.3% return, outperforming this stock by 194.8%

Institutional Holdings

  • FMR Inc

    6.40%
  • Deerfield Management Co

    4.52%
  • Vanguard Group Inc

    2.40%
  • Balyasny Asset Management LLC

    2.32%
  • Kent Lake Capital LLC

    1.60%
  • Hongkou Capital LP

    1.19%

Company Information

the oncology institute of hope and innovation is a premier cancer treatment center in los angeles. offering programs to help patients and families cope with the challenges that are brought on by cancer and strive to optimize their quality of life, comprehensive and realistic treatment goals are tailored to every person's unique needs and decided upon in partnership with the patients and their families. dedicated to excel in cancer prevention, diagnosis and education through our exceptional team of physicians, nurse practitioners, nurses, medical assistants and office staff, the oncology institute of hope and innovation has 8 southern california locations in the cities of downey, long beach, lynwood, montebello whittier, anaheim, la mirada and glendale. for more information please visit www.theoncologyinstitute.com.

Organization
Oncology Institute Inc/the
Employees
800
CEO
Mr. Richard Alan Barasch
Industry
Financial

FAQs